

OMB No. 0651-0011 (exp. 4/94)

03-03-2003



To the Honorable Commissioner of P

102378755

Attached original documents or copy thereof.

1. Name of conveying party(ies):

Novartis Corporation

2.25.03

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other To Correct Assignment previously filed on
August 21, 2001 at Reel/Frame: 013211/0308 which
erroneously listed the receiving party name.

Execution Date: December 19, 2002

2. Name and address of receiving party(ies)

Name: Sinnreich Technologien GmbH

Internal Address: _____

Street Address: Hohe Windestrasse 98

City: Basel/BS State: CH ZIP: 4059

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

B. Patent No.(s)

5,827,984

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Thomas Hoxie

Internal Address: Novartis

Street Address: One Health Plaza

City: East Hanover State: NJ ZIP: 07936

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41) \$ 40

☐ Enclosed

☒ Authorized to be charged to deposit account and any other additional fees required.

8. Deposit account number:

19-0134 (in the name of Novartis)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John D. Thallemer

Name of Person Signing
Reg. No. 34,940

John Thallemer
Signature

February 25, 2003

Date

☒ Certificate of mailing on reverse side

Total number of pages including cover sheet, attachments, and document: 2

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

02/28/2003 LMUELLER 00000171 190134 5827984

01 FC:8021

40.00 CH

PATENT
REEL: 013791 FRAME: 0207

ASSIGNMENT

Whereas, Novartis Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in United States Patent 5,827,984 by virtue of an Assignment from Joel Sinnreich and Christian Bosshard recorded in the Patent and Trademark Office on November 12, 1996 (Reel 8216, Frame 0088);

Whereas, Novartis Corporation was formerly known as Ciba-Geigy Corporation, the change of name having been recorded in the Patent and Trademark Office on October 13, 1998 (Reel 9507, Frames 0112-0114); and

Whereas, Novartis Corporation wishes to assign its entire interest in United States Patent 5,827,984 to Sinnreich Technologien GmbH, Hohe Windestrasse 98, 4059 Basel/BS, Switzerland, a corporation of Switzerland, and said Sinnreich Technologien GmbH wishes to acquire said patent.

Now, therefore, Novartis Corporation hereby assigns to Sinnreich Technologien GmbH and its successors and assigns its entire right, title and interest in (a) United States Patent 5,827,984, (b) any and all applications for reissues of said patent, (c) any and all reissues of said patent that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Corporation to Sinnreich Technologien GmbH constituting the entire right, title and interest in said patents (including reissue patents), extensions and reexamination certificates.

In witness whereof, Novartis Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 19th day of December 2002.

Novartis Corporation



Thomas Hoxie
Vice-President